TMO Share Price | Thermo Fisher Scientific, Inc. Stock Analysis & Recommendation

Q: How big is Thermo Fisher Scientific, Inc.?

Market Cap: As of Jun 18, Thermo Fisher Scientific, Inc. has a market capitalization of 164,766.10 million, classifying it as a Large Cap company.Recent Quarterly Performance: For the latest four quarters, Thermo Fisher Scientific, Inc. reported net sales of 42,898.00 million and a net profit of 6,519.00 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 49,584.00 million and total assets of 97,321.00 million.

Q: What does Thermo Fisher Scientific, Inc. do?

Overview: Thermo Fisher Scientific, Inc. develops, manufactures, and sells a range of products in the Pharmaceuticals & Biotechnology industry, and it operates within the large-cap market segment.Financial Snapshot: Most recent Net Sales: 10,364 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 1,511 Million (Quarterly Results - Mar 2025) Market cap: USD 164,766.10 Million (Large Cap)Key Metrics: P/E: 26.00 Dividend Yield: 0.38% Debt Equity: 0.57 Return on Equity: 13.42% Price to Book: 3.34Contact Details: Address: 168 3rd Ave, WALTHAM MA: 02451-7551 Tel: ['1 781 6221000', '1 781 6221111'] Fax: 1 781 6221207 Website: https://www.thermofisher.com/

Q: Is Thermo Fisher Scientific, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Thermo Fisher Scientific, Inc. moved from expensive to fair. Based on the current metrics, the company appears fairly valued. Key ratios include a P/E ratio of 26, an EV to EBITDA of 18.39, and a Price to Book Value of 3.44. In comparison to peers, Abbott Laboratories has a P/E of 18.36 and Medtronic Plc has an EV to EBITDA of 15.08, indicating that Thermo Fisher is positioned competitively within its industry.In terms of recent performance, Thermo Fisher's stock returned 2.69% over the past week, outperforming the S&P 500's return of 1.70%. However, its one-year return of -10.07% lags behind the S&P 500's 14.08%, suggesting that while the stock is currently fairly valued, it has struggled to keep pace with broader market trends.

Q: Is Thermo Fisher Scientific, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Thermo Fisher Scientific, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages also indicate a bullish stance. However, the weekly RSI is bearish, and the KST shows a bullish weekly signal but a bearish monthly signal. Dow Theory reflects a mildly bullish stance on both weekly and monthly time frames. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 6.23% and 22.33%, respectively, compared to the S&P 500's 1.92% and 2.32%. However, over longer periods, the stock has underperformed the benchmark, particularly in the 3-year and 5-year returns. Overall, the current technical stance is bullish, with moderate strength driven by the positive signals from MACD and Bollinger Bands.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.64 M

Shareholding (Dec 2025)

FII

29.05%

Held by 750 FIIs

DII

37.19%

Held by 73 DIIs

Promoter

0.10%

How big is Thermo Fisher Scientific, Inc.?

22-Jun-2025

As of Jun 18, Thermo Fisher Scientific, Inc. has a market capitalization of $164.77 billion, with net sales of $42.90 billion and a net profit of $6.52 billion over the latest four quarters.

View full answer

What does Thermo Fisher Scientific, Inc. do?

22-Jun-2025

Thermo Fisher Scientific, Inc. develops and sells products in the Pharmaceuticals & Biotechnology industry, with recent net sales of $10.36 billion and a market cap of $164.77 billion. Key metrics include a P/E ratio of 26.00 and a dividend yield of 0.38%.

View full answer

Who are in the management team of Thermo Fisher Scientific, Inc.?

22-Jun-2025

As of March 2022, the management team of Thermo Fisher Scientific, Inc. includes Marc Casper (Chairman, President, and CEO), Thomas Lynch (Lead Independent Director), R. Alexandra Keith, Nelson Chai, C. Martin Harris, and Tyler Jacks (all Independent Directors). They are responsible for guiding the company's strategic direction and operations.

View full answer

Is Thermo Fisher Scientific, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Thermo Fisher Scientific, Inc. is fairly valued with a P/E ratio of 26 and an EV to EBITDA of 18.39, having recently outperformed the S&P 500 over the past week but lagging behind in one-year returns.

View full answer

Is Thermo Fisher Scientific, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Thermo Fisher Scientific, Inc. shows a bullish technical trend with positive signals from MACD and Bollinger Bands, despite a bearish weekly RSI and underperformance over longer periods compared to the S&P 500.

View full answer

Compare Thermo Fisher Scientific, Inc. with Similar Stocks

Abbott Laboratories Danaher Corp.Stryker Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 11.00

Healthy long term growth as Net Sales has grown by an annual rate of 10.48% and Operating profit at 11.37%

Flat results in Jun 25

With ROCE of 10.03%, it has a attractive valuation with a 2.55 Enterprise value to Capital Employed

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 214,800 Million (Large Cap)

P/E

34.00

Industry P/E

Dividend Yield

0.30%

Debt Equity

0.55

Return on Equity

13.02%

Price to Book

4.02

Revenue and Profits:

Net Sales:

12,215 Million

(Quarterly Results - Dec 2025)

Net Profit:

1,970 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-12.36%

6 Months

1.9%

1 Year

-4.87%

2 Years

-15.14%

3 Years

-10.12%

4 Years

-8.29%

5 Years

12.33%

Thermo Fisher Scientific, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

6.70%

EBIT Growth (5y)

0.80%

EBIT to Interest (avg)

11.00

Debt to EBITDA (avg)

2.32

Net Debt to Equity (avg)

0.57

Sales to Capital Employed (avg)

0.51

Tax Ratio

6.68%

Dividend Payout Ratio

9.70%

Pledged Shares

Institutional Holding

93.26%

ROCE (avg)

13.03%

ROE (avg)

16.96%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.55

EV to EBIT

32.43

EV to EBITDA

23.84

EV to Capital Employed

3.26

EV to Sales

5.98

PEG Ratio

3.02

Dividend Yield

0.28%

ROCE (Latest)

10.05%

ROE (Latest)

13.56%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 255 Schemes (33.63%)

Foreign Institutions

Held by 750 Foreign Institutions (29.05%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 9.83% vs 2.46% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 21.53% vs 0.12% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "12,215.00",
          "val2": "11,122.00",
          "chgp": "9.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,181.00",
          "val2": "2,815.00",
          "chgp": "13.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "474.00",
          "val2": "414.00",
          "chgp": "14.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-89.00",
          "val2": "-117.00",
          "chgp": "23.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,970.00",
          "val2": "1,621.00",
          "chgp": "21.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "200.90%",
          "val2": "193.70%",
          "chgp": "0.72%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 3.91% vs 0.05% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 6.03% vs 6.43% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "44,556.00",
          "val2": "42,879.00",
          "chgp": "3.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "11,178.00",
          "val2": "10,770.00",
          "chgp": "3.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1,703.00",
          "val2": "1,654.00",
          "chgp": "2.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-298.00",
          "val2": "-73.00",
          "chgp": "-308.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6,720.00",
          "val2": "6,338.00",
          "chgp": "6.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "188.50%",
          "val2": "178.70%",
          "chgp": "0.98%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

12,215.00

11,122.00

9.83%

Operating Profit (PBDIT) excl Other Income

3,181.00

2,815.00

13.00%

Interest

474.00

414.00

14.49%

Exceptional Items

-89.00

-117.00

23.93%

Consolidate Net Profit

1,970.00

1,621.00

21.53%

Operating Profit Margin (Excl OI)

200.90%

193.70%

0.72%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 9.83% vs 2.46% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 21.53% vs 0.12% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

44,556.00

42,879.00

3.91%

Operating Profit (PBDIT) excl Other Income

11,178.00

10,770.00

3.79%

Interest

1,703.00

1,654.00

2.96%

Exceptional Items

-298.00

-73.00

-308.22%

Consolidate Net Profit

6,720.00

6,338.00

6.03%

Operating Profit Margin (Excl OI)

188.50%

178.70%

0.98%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 3.91% vs 0.05% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 6.03% vs 6.43% in Dec 2024

All Annual Results

Company CV

About Thermo Fisher Scientific, Inc.

Thermo Fisher Scientific, Inc.

Pharmaceuticals & Biotechnology

Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. It offers its products and services through various brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services. Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines. Analytical Instruments segment provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory. Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Services segment offers products and solutions needed for the laboratory.

Company Coordinates

Company Details

168 3rd Ave , WALTHAM MA : 02451-7551

Tel: 1 781 62210001 781 6221111

https://www.thermofisher.com/

Registrar Details